Table 2.
The main effect of COMT Val158Met polymorphism and its interaction with MPO T-764C polymorphism on breast cancer risk.
| Cases (%) | Controls (%) | OR (95%CI)a | |
|---|---|---|---|
| COMT Genotype* | 1212(100)† | 1683(100) | |
| Val/Val | 271(22.4) | 400(23.8) | 1.00(Ref) |
| Val/Met | 607(50.1) | 837(49.7) | 1.02(0.83, 1.24) |
| Met/Met | 334(27.6) | 446(26.5) | 1.02(0.82, 1.28) |
| Val/Val | 271(22.4) | 400(23.8) | 1.00(Ref) |
| Val/Met + Met/Met | 941(77.6) | 1283(76.2) | 1.02(0.84, 1.23) |
|
| |||
| COMT | MPO Genotype*¶ | 1175(100)† | 1631(100)† | |
| Met158 Met | MPO T-764T | 204 (17.4) | 280 (17.2) | 1.00 (Ref) |
| Met158 Met | MPO T-764C | 105 (8.9) | 141 (8.7) | 0.98 (0.71, 1.37) |
| Met158 Met | MPO C-764C | 11 (0.9) | 13 (0.8) | 1.21 (0.51, 2.86) |
| Met158 Val | MPO T-764T | 369 (31.4) | 500 (30.7) | 1.03 (0.81, 1.31) |
| Met158 Val | MPO T-764C | 202 (17.2) | 266 (16.3) | 1.11 (0.84, 1.46) |
| Met158 Val | MPO C-764C | 25 (2.1) | 39 (2.4) | 0.88 (0.51, 1.53) |
| Val158 Val | MPO T-764T | 169 (14.4) | 252 (15.5) | 0.99 (0.74, 1.31) |
| Val158 Val | MPO T-764C | 86 (7.3) | 123 (7.5) | 1.08 (0.76, 1.54) |
| Val158 Val | MPO C-764C | 4 (0.3) | 17 (1.0) | 0.28 (0.08, 1.00) |
a
Unconditional logistic regression adjusted for the matching factors and BMI at age 18, weight gain since age 18, age at menarche, personal history of benign breast disease, first-degree family history of breast cancer, age at first birth/parity, age at menopause, and duration of postmenopausal hormone use.
*
Numbers do not add to the total number of women due to missing values in genotyping or covariates.
†
The sum of percentage does not add up to 100 due to rounding.
¶
P-interaction = 0.57